mirror of
https://github.com/msberends/AMR.git
synced 2026-11-16 07:50:50 +01:00
Update taxonomy of microorganisms (2026-10) (#312)
* Update taxonomy of microorganisms (2026-10) Rebuild of the microorganisms data set from COL 2026-04-18 XR, LPSN and BacDive of October 2026 and MycoBank of January 2026, with v3.0.1 as the previous data set: 111,103 records (v3.0.1: 78,679), 0 changed MO codes of existing names, 522 released codes retired (275 to be reviewed). Script fixes (data-raw/_reproduction_scripts/reproduction_of_microorganisms.R): - previous data set from the last release; COL read as COL Data Package (NameUsage.tsv) - keep COL records without authors (a filter on NA dropped them, e.g. Balamuthia mandrillaris) - genus homonyms: unclassified MycoBank entries are not authoritative; the released domain of a genus wins if a source supports it (e.g. Moorella, Serpula, Pirella stay Bacteria) - protect current names of relevant species instead of whole current genera (data set tripled) - current names and synonyms only within the same domain and for known names (Brugia -> Lycoperdon) - MycoBank names in Latin script only; old records outside their source's scope become manually added - Graphium butterflies of v3.0.1 are not carried over, re-added or restored - restore released taxa by name and rank; retire older cross-domain homonyms for review - fill empty families from COL and a commented override list (Ascaris, Balamuthia) - add Brugia malayi and B. timori; remove Salmonella species synonyms that are serovars - BacDive: a minority of facultative strain records no longer decides (C. difficile) - translate codes of other data sets with the development version; review unmatched codes - scope decisions: COL XR names only if relevant or released; Protozoa follow the Fungi rules Also: all checkpoints (data-raw/taxonomy*.rds), updated data sets, Bartlett et al. list, accessed dates in TAXONOMY_VERSION, NEWS, two staphylococci added to CoNS, tests updated for real taxonomic changes, known defects file removed (all solved), and the findings report with all review files in data-raw/taxonomy_review/2026-10/. Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy review report: note on the .dta export and the single commit Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Fix as.mo() for Salmonella serovars written with the species; add S. xeri to CoNS - "Salmonella enterica (subsp. enterica) serovar Typhi" returned S. bongori, and "S. enterica Typhimurium" S. enterica diarizonae; "Paratyphi A/B/C" became serogroups - Staphylococcus xeri and S. parequorum confirmed as coagulase-negative Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy build: remove lichens (decision of 5 October 2026) Fungi in the lichen-forming classes and the order Verrucariales are removed unless their genus is clinically relevant, with the synonyms that point to them (4,155 records); released lichens are restored. microorganisms now has 107,126 records (Fungi 45,739); all tests pass. Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy review decisions: microsporidia in Fungi, accepted names, missing protozoa - all microsporidia in the Fungi (1,394 names of v3.0.1 from P_ to F_, old codes translated by name) - Enterocytozoon bieneusi and Encephalitozoon cuniculi as accepted names (accepted_name_override) - Balantidium and Isospora added to MO_RELEVANT_GENERA; Cystoisospora belli as synonym of Isospora belli - synonym cycles decided: Capillidium and Scolecobasidium are the current genera - removed the stale data-raw/taxonomy_lpsn0.rds - microorganisms now has 107,253 records; all tests pass Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy review report: all items reviewed Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Rule matching by accepted taxon; Erysipelatoclostridium as synonym of Thomasclavelia - interpretive_rules(): species named in a rule (literal names, genus_species/fullname) now also match all other names of the same accepted taxon, e.g. 'Clostridium ramosum' for Thomasclavelia ramosa; not for genera or regex rules - Erysipelatoclostridium and its species are synonyms of Thomasclavelia (accepted_name_override); E. merdavium is retired by decision of 6 October 2026, and the build removes taxa retired by a human decision - microorganisms patched with the same logic as the build script (no full rebuild): 107,252 records - intrinsic_resistant regenerated with the new taxonomy and rule matching: 308,646 rows - clinical_breakpoints: EUCAST workbook rows merged again, 24 EUCAST 2026 rows moved from C. ramosum to T. ramosa Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy: correct records for names listed twice, no synonyms without a current name, strict data tests - one record per name keeps the accepted record (e.g. Eggerthella lenta, Gordonia amarae, Anisakis simplex and Enterobius vermicularis were synonyms without a current name), links to dropped records are moved - LPSN lookup reads the taxonomic status and correct name; validly published synonyms are no longer 'accepted' - synonyms without a current name: linked via LPSN or removed, released codes retired (3,668); records with kept children become 'unknown'; the M. tuberculosis complex is protected (decisions of 7 October 2026) - subspecies codes reserved, current names of synonyms kept when pruning, missing parent records added or moved, higher taxonomy harmonised, shared identifiers resolved per domain and rank, pointers and parent links cleaned - data sets refer only to current names (except intrinsic_resistant); group members only from current names; internal CoNS/CoPS/streptococcal lists keep a synonym only with its current name - intrinsic_resistant, clinical_breakpoints (EUCAST workbooks) and microorganisms.groups regenerated - 28 new tests in test-data.R; devtools::test(): 1,581 expectations, 0 failures - open decisions listed in data-raw/taxonomy_review/2026-10/REPORT.md, section 6 Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy: protect WHO priority genera, follow LPSN for the M. tuberculosis complex, place protist groups in one domain - all taxa of the genera in MO_WHO_PRIORITY_GENERA are protected, also names that are not validly published (replaces the hard-coded M. tuberculosis complex; keeps e.g. Klebsiella quasivariicola, M. canettii, M. orygis) - LPSN is followed for the M. tuberculosis complex: M. bovis, M. africanum, M. caprae, M. microti and M. pinnipedii are heterotypic synonyms of M. tuberculosis (Riojas et al. 2018); a test enforces this - labyrinthulids in the Chromista (Aplanochytrium), Dictydiaethalium in the Protozoa (genus_domain_move), and the rank suffix also between domains ('Acantharia {class}' next to the fungal genus Acantharia) - devtools::test(): 1,582 expectations, 0 failures Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy build no longer depends on the previous build - intrinsic_resistant is no input of the microorganisms build anymore (it is computed from it); the genera named in the interpretive rules are read from the rules instead - the previous data set no longer makes genera relevant; Debaryomyces added to MO_RELEVANT_GENERA - new run_after_microorganisms_build.R recreates microorganisms.groups, the EUCAST breakpoints and intrinsic_resistant in the right order, and the build runs it at its end - reproduction_of_intrinsic_resistant.R uses devtools::load_all() instead of the installed package - effect: 24 never released, not relevant COL records less; devtools::test(): 1,582 expectations, 0 failures Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * Taxonomy review report: summary updated to the second round Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> * MO code retirements: mark the 265 reviewed retirements as reviewed The Graphium and v2.x Protozoa retirements were reviewed and accepted on 6 October 2026 (see the taxonomy review report, section 5); 'NEEDS REVIEW' is replaced by 'reviewed by Matthijs S. Berends on 2026-10-06'. Co-Authored-By: Claude Opus 5.5 <noreply@anthropic.com> --------- Co-authored-by: Claude Opus 5.5 <noreply@anthropic.com>
This commit is contained in:
1 parent
4aafe9a676
commit
0ca43df459
148 files changed
+146598
-67161
No files matched your search
@@ -787,30 +787,6 @@
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_PRFR" 2 "TZP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.5 0.5 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_PRFR" 2 "VAN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "5 mcg" 12 12 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_PRFR" 2 "VAN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 2 2 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "AMC" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "2/1 mcg" 21 21 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "AMC" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "AMP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "2 mcg" 20 20 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "AMP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2.1 "AMX" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "AMX" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2.1 "CLI" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2.1 "CLI" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2.1 "ETP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives IE (insufficient evidence)"
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2.1 "ETP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives IE (insufficient evidence)"
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "IPM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "10 mcg" 26 26 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "IPM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.5 0.5 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "MEM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "10 mcg" 22 22 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "MEM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 2 2 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "MTR" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "5 mcg" 21 21 FALSE FALSE "[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "MTR" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 4 4 FALSE FALSE "[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "PEN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "1 unit" 21 21 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "PEN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "SAM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "10/10 mcg" 26 26 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "SAM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2 "TZP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "30/6 mcg" 28 28 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2 "TZP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.5 0.5 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_RMSM" 2.1 "VAN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_RMSM" 2.1 "VAN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_SPTC" 2 "AMC" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "2/1 mcg" 25 25 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_CTRDM_SPTC" 2.1 "AMC" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_CTRDM_SPTC" 2 "AMP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "2 mcg" 25 25 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
@@ -2045,9 +2021,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_KLBSL_PNMN" 2 "TOB" "ECOFF" 2 2 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "DISK" "B_KLBSL_PNMN" 2 "TZP" "ECOFF" "30/6 mcg" 17 17 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_KLBSL_PNMN" 2 "TZP" "ECOFF" 8 8 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LCTBC_RHMN" 2 "AMP" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LCTBC_RHMN" 2 "GEN" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LCTBC_RHMN" 2 "TCY" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LCTCS_RHMN" 2 "AMP" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LCTCS_RHMN" 2 "GEN" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LCTCS_RHMN" 2 "TCY" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "DISK" "B_LISTR_MNCY" 2 "AMP" "ECOFF" "2 mcg" 15 15 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "AMP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "DISK" "Intravenous" "B_LISTR_MNCY" 2 "AMP" "L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)" "2 mcg" 16 16 FALSE FALSE
|
||||
@@ -2077,7 +2053,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "TZP" "ECOFF" 8 8 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "VAN" "ECOFF" 2 2 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_MMPSS_BOVS" 2 "ENR" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_MMPSS_BOVS" 2 "FLR" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_MNNHM_HMLY" 2 "AMC" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
@@ -3340,6 +3315,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -3500,6 +3476,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" 2 2 FALSE FALSE "[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -3549,7 +3526,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -3591,6 +3570,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CLI" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "DAP" "ECOFF" 1 1 FALSE FALSE
|
||||
@@ -3627,6 +3607,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMNS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "AMP" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "AMX" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "ENR" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
@@ -3669,10 +3650,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_PSDN" 2 "AMC" "ECOFF" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_PSDN" 2 "CLI" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
@@ -3712,6 +3695,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_SCHL" 2 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "1 mcg" 20 20 FALSE FALSE "[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_STPHY_SCHL" 2.1 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "DISK" "B_STPHY_SPRP" 2 "AMP" "ECOFF" "2 mcg" 17 17 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_SPRP" 2 "AMP" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
@@ -3740,7 +3724,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "BPR" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "FOX" "ECOFF" 4 4 FALSE FALSE
|
||||
@@ -3749,6 +3732,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "LVX" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "OXA" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported \"susceptible, increased exposure\" (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -4621,14 +4605,30 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_STRPT_VIRI" 2.5 "VAN" "Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)" "5 mcg" 15 15 FALSE FALSE "[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "VAN" "Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)" 2 2 FALSE FALSE "[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_STTZR_STTZ" 2 "TZP" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "AMO" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "TRB" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "AMO" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "TRB" "Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "VOR" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "AMC" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "2/1 mcg" 21 21 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "AMC" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "AMP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "2 mcg" 20 20 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "AMP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2.1 "AMX" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "AMX" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2.1 "CLI" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2.1 "CLI" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2.1 "ETP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives IE (insufficient evidence)"
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2.1 "ETP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives IE (insufficient evidence)"
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "IPM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "10 mcg" 26 26 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "IPM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.5 0.5 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "MEM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "10 mcg" 22 22 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "MEM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 2 2 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "MTR" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "5 mcg" 21 21 FALSE FALSE "[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "MTR" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 4 4 FALSE FALSE "[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "PEN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "1 unit" 21 21 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "PEN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "SAM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "10/10 mcg" 26 26 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "SAM" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.25 0.25 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2 "TZP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" "30/6 mcg" 28 28 FALSE FALSE "[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2 "TZP" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" 0.5 0.5 FALSE FALSE "[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L."
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_THMSC_RAMS" 2.1 "VAN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_THMSC_RAMS" 2.1 "VAN" "Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)" FALSE FALSE "[No breakpoint] EUCAST gives - (susceptibility testing is not recommended)"
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_VIBRI" 3 "AZM" "Vibrio (file: Clinical Breakpoint Tables v. 16.1)" "15 mcg" 16 16 FALSE FALSE "[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
||||
"EUCAST 2026" "human" "human" "MIC" "B_VIBRI" 3 "AZM" "Vibrio (file: Clinical Breakpoint Tables v. 16.1)" 4 4 FALSE FALSE
|
||||
"EUCAST 2026" "human" "human" "DISK" "B_VIBRI" 3 "CAZ" "Vibrio (file: Clinical Breakpoint Tables v. 16.1)" "10 mcg" 22 22 FALSE FALSE
|
||||
@@ -5109,6 +5109,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
|
||||
"EUCAST 2026" "human" "human" "MIC" "F_PICHI_KDRV" 2.1 "VOR" "5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)" FALSE FALSE "[No breakpoint] EUCAST gives IE (insufficient evidence) | [5] The ECOFFs for these species are in general higher than for C. albicans."
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "AMB" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "ITR" "Antifungal ECOFFs" 2 2 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "AMO" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "TRB" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "AMO" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "TRB" "Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "VOR" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_ACHRMB_XYLS" 2.1 "FDC" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_ACHRMB_XYLS" 2.1 "FDC" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values <=0.5 mg/L (zone diameter >=26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/."
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_ACHRMB_XYLS" 2 "MEM" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)" "10 mcg" 26 20 FALSE FALSE
|
||||
@@ -6973,9 +6981,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_KLBSL_PNMN" 2 "TOB" "ECOFF" 2 2 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "DISK" "B_KLBSL_PNMN" 2 "TZP" "ECOFF" "30/6 mcg" 17 17 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_KLBSL_PNMN" 2 "TZP" "ECOFF" 8 8 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LCTBC_RHMN" 2 "AMP" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LCTBC_RHMN" 2 "GEN" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LCTBC_RHMN" 2 "TCY" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LCTCS_RHMN" 2 "AMP" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LCTCS_RHMN" 2 "GEN" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LCTCS_RHMN" 2 "TCY" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "DISK" "B_LISTR_MNCY" 2 "AMP" "ECOFF" "2 mcg" 15 15 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "AMP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "human" "human" "DISK" "Intravenous" "B_LISTR_MNCY" 2 "AMP" "L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)" "2 mcg" 16 16 FALSE FALSE
|
||||
@@ -7005,7 +7013,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "TZP" "ECOFF" 8 8 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "VAN" "ECOFF" 2 2 FALSE FALSE
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_MMPSS_BOVS" 2 "ENR" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_MMPSS_BOVS" 2 "FLR" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_MNNHM_HMLY" 2 "AMC" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
@@ -8190,6 +8197,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -8348,6 +8356,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" 2 2 FALSE FALSE "[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -8397,7 +8406,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -8439,6 +8450,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CLI" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "DAP" "ECOFF" 1 1 FALSE FALSE
|
||||
@@ -8475,6 +8487,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMNS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "AMP" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "AMX" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "ENR" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
@@ -8517,10 +8530,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_PSDN" 2 "AMC" "ECOFF" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_PSDN" 2 "CLI" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
@@ -8560,6 +8575,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_SCHL" 2 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "1 mcg" 20 20 FALSE FALSE "[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_STPHY_SCHL" 2.1 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "DISK" "B_STPHY_SPRP" 2 "AMP" "ECOFF" "2 mcg" 17 17 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_SPRP" 2 "AMP" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
@@ -8586,7 +8602,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "BPR" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "FOX" "ECOFF" 4 4 FALSE FALSE
|
||||
@@ -8595,6 +8610,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "LVX" "ECOFF" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "OXA" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -9467,14 +9483,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_STRPT_VIRI" 2.5 "VAN" "Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)" "5 mcg" 15 15 FALSE FALSE "[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "VAN" "Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)" 2 2 FALSE FALSE "[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_STTZR_STTZ" 2 "TZP" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "AMO" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "TRB" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "AMO" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "TRB" "Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "VOR" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_VIBRI" 3 "AZM" "Vibrio (file: Clinical Breakpoint Tables v. 15.0)" "15 mcg" 16 16 FALSE FALSE "[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
||||
"EUCAST 2025" "human" "human" "MIC" "B_VIBRI" 3 "AZM" "Vibrio (file: Clinical Breakpoint Tables v. 15.0)" 4 4 FALSE FALSE
|
||||
"EUCAST 2025" "human" "human" "DISK" "B_VIBRI" 3 "CAZ" "Vibrio (file: Clinical Breakpoint Tables v. 15.0)" "10 mcg" 22 22 FALSE FALSE
|
||||
@@ -9874,6 +9882,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_NKSMY_BRTS" 2 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "AMB" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "ITR" "Antifungal ECOFFs" 2 2 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "AMO" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "TRB" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "AMO" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "TRB" "Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "VOR" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_ACHRMB_XYLS" 2 "MEM" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)" "10 mcg" 26 20 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_ACHRMB_XYLS" 2 "MEM" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)" 1 4 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_ACHRMB_XYLS" 2 "SXT" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)" "1.25/23.75 mcg" 26 26 FALSE FALSE "[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
@@ -11306,7 +11322,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "DISK" "B_LISTR_MNCY" 2 "SXT" "ECOFF" "1.25/23.75 mcg" 28 28 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)" "1.25/23.75 mcg" 29 29 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "animal" "cattle" "MIC" "Respiratory" "B_MNNHM_HMLY" 2 "FLR" "Histophilus somni" 2 4 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "DISK" "B_MRGNL_MRGN" 2 "AMP" "ECOFF" "10 mcg" 14 14 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "DISK" "B_MRGNL_MRGN" 2 "CAZ" "ECOFF" "10 mcg" 22 22 FALSE FALSE
|
||||
@@ -12178,6 +12193,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm d
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -12268,6 +12284,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" 2 2 FALSE FALSE "[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -12320,7 +12337,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -12342,11 +12361,13 @@ ND = No ECOFF available."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_HMLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "DISK" "B_STPHY_HMNS" 2 "FOX" "ECOFF" "30 mcg" 22 22 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_HMNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_STPHY_INTR" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STPHY_INTR" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_INTR" 2 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "1 mcg" 20 20 FALSE FALSE "[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
||||
@@ -12368,10 +12389,12 @@ ND = No ECOFF available."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
@@ -12390,6 +12413,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_SCHL" 2 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "1 mcg" 20 20 FALSE FALSE "[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STPHY_SCHL" 2.1 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "DISK" "B_STPHY_SPRP" 2 "AMP" "ECOFF" "2 mcg" 17 17 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_STPHY_SPRP" 2 "AMP" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "2 mcg" 18 18 FALSE FALSE "[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
@@ -12408,9 +12432,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_WRNR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -13039,14 +13063,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STRPT_VIRI" 2.6 "TZP" "Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with \"Note\"). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_STRPT_VIRI" 2.5 "VAN" "Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)" "5 mcg" 15 15 FALSE FALSE "[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "VAN" "Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)" 2 2 FALSE FALSE "[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "AMO" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "TRB" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "AMO" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "TRB" "Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "VOR" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_VIBRI" 3 "AZM" "Vibrio (file: Clinical Breakpoint Tables v. 14.0)" "15 mcg" 16 16 FALSE FALSE "[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test."
|
||||
"EUCAST 2024" "human" "human" "MIC" "B_VIBRI" 3 "AZM" "Vibrio (file: Clinical Breakpoint Tables v. 14.0)" 4 4 FALSE FALSE
|
||||
"EUCAST 2024" "human" "human" "DISK" "B_VIBRI" 3 "CAZ" "Vibrio (file: Clinical Breakpoint Tables v. 14.0)" "10 mcg" 22 22 FALSE FALSE
|
||||
@@ -13412,6 +13428,14 @@ Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminogl
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_NKSMY_BRTS" 2 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "AMB" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "ITR" "Antifungal ECOFFs" 2 2 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "AMO" "Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "TRB" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "VOR" "Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "AMO" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "ITR" "Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "TRB" "Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"EUCAST 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "VOR" "Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_ACHRMB_XYLS" 2 "MEM" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)" "10 mcg" 26 20 FALSE FALSE
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_ACHRMB_XYLS" 2 "MEM" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)" 1 4 FALSE FALSE
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_ACHRMB_XYLS" 2 "SXT" "A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)" "1.25/23.75 mcg" 26 26 FALSE FALSE "[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
@@ -14755,7 +14779,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2023" "human" "human" "MIC" "Non-meningitis" "B_LISTR_MNCY" 2 "PEN" "L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)" 1 1 FALSE FALSE
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)" "1.25/23.75 mcg" 29 29 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "animal" "cattle" "MIC" "Respiratory" "B_MNNHM_HMLY" 2 "FLR" "Histophilus somni" 2 4 FALSE FALSE
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_MRXLL_CTRR" 2 "AMC" "M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)" "2/1 mcg" 19 19 FALSE FALSE
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_MRXLL_CTRR" 2 "AMC" "M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)" 1 1 FALSE FALSE "[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
||||
@@ -15568,6 +15591,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -15633,6 +15657,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" 2 2 FALSE FALSE "[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -15672,7 +15697,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
@@ -15685,10 +15712,12 @@ ND = No ECOFF available."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_HMLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_HMNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_KLOS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_LGDN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 27 27 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_STPHY_LGDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST excludes Staphylococcus lugdunensis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
|
||||
@@ -15699,10 +15728,12 @@ ND = No ECOFF available."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
@@ -15721,6 +15752,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_SCHL" 2 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "1 mcg" 20 20 FALSE FALSE "[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_STPHY_SCHL" 2.1 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_STPHY_SPRP" 2 "AMP" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "2 mcg" 18 18 FALSE FALSE "[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_STPHY_SPRP" 2.1 "AMP" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
@@ -15733,9 +15765,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_WRNR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant."
|
||||
"EUCAST 2023" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
"EUCAST 2023" "human" "human" "MIC" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -17901,7 +17933,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2022" "human" "human" "MIC" "Non-meningitis" "B_LISTR_MNCY" 2 "PEN" "L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)" 1 1 FALSE FALSE
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)" "1.25/23.75 mcg" 29 29 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "animal" "cattle" "MIC" "Respiratory" "B_MNNHM_HMLY" 2 "FLR" "Histophilus somni" 2 4 FALSE FALSE
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_MRXLL_CTRR" 2 "AMC" "M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)" "2/1 mcg" 19 19 FALSE FALSE
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_MRXLL_CTRR" 2 "AMC" "M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)" 1 1 FALSE FALSE "[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L."
|
||||
@@ -18716,6 +18747,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -18779,6 +18811,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" 2 2 FALSE FALSE "[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -18816,7 +18849,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -18829,10 +18864,12 @@ ND = No ECOFF available."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_HMLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_HMNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_KLOS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_LGDN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 27 27 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_STPHY_LGDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST excludes Staphylococcus lugdunensis ('S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis')"
|
||||
@@ -18843,10 +18880,12 @@ ND = No ECOFF available."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
@@ -18865,6 +18904,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_SCHL" 2 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "1 mcg" 20 20 FALSE FALSE "[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans."
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_STPHY_SCHL" 2.1 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_STPHY_SPRP" 2 "AMP" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "2 mcg" 18 18 FALSE FALSE "[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_STPHY_SPRP" 2.1 "AMP" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
@@ -18877,9 +18917,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_WRNR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2022" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
"EUCAST 2022" "human" "human" "MIC" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -21606,7 +21646,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2021" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "TCY" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "TZP" "ECOFF" 8 8 FALSE FALSE
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_MNNHM_HMLY" 2 "FLR" "ECOFF" 2 2 FALSE FALSE
|
||||
"EUCAST 2021" "animal" "cattle" "MIC" "Respiratory" "B_MNNHM_HMLY" 2 "FLR" "Florfenicol rationale" 2 4 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_MNNHM_HMLY" 2 "TCY" "ECOFF" 2 2 FALSE FALSE
|
||||
@@ -22593,6 +22632,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2021" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactam ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2021" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2021" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -22724,11 +22764,11 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2021" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" 2 2 FALSE FALSE "[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CASE" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CGLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CHRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CLDN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CNDM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -22791,7 +22831,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -22825,6 +22867,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CLI" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "DAP" "ECOFF" 1 1 FALSE FALSE
|
||||
@@ -22850,6 +22893,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMNS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "CHL" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "ERY" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
@@ -22875,10 +22919,12 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
"EUCAST 2021" "human" "human" "MIC" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [5] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm."
|
||||
@@ -22898,6 +22944,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "human" "human" "MIC" "B_STPHY_SCHL" 2.1 "OXA" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_SCIR" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_SMLN" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_SMLN" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
@@ -22922,7 +22969,6 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "ERY" "ECOFF" 1 1 FALSE FALSE
|
||||
@@ -22932,6 +22978,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "MFX" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "RXT" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2021" "ECOFF" "ECOFF" "MIC" "B_STPHY_XYLS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2021" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -25788,7 +25835,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2020" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "TCY" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_LISTR_MNCY" 2 "TZP" "ECOFF" 8 8 FALSE FALSE
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_MNNHM_HMLY" 2 "FLR" "ECOFF" 2 2 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_MNNHM_HMLY" 2 "TCY" "ECOFF" 2 2 FALSE FALSE
|
||||
"EUCAST 2020" "human" "human" "DISK" "B_MRGNL" 3.1 "IMR" "Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST excludes Morganella spp. ('Enterobacterales except Morganella spp.')"
|
||||
@@ -26748,6 +26794,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2020" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Staphylococci that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Staphylococci that test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Staphylococci that test resistant to cefoxitin are resistant to all penicillins. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2020" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2020" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -26879,11 +26926,11 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2020" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" 2 2 FALSE FALSE "[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CASE" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CGLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CHRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CLDN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CNDM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -26948,7 +26995,9 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -26982,6 +27031,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "CLI" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMLY" 2 "DAP" "ECOFF" 1 1 FALSE FALSE
|
||||
@@ -27007,6 +27057,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_HMNS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "CHL" "ECOFF" 16 16 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "ERY" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_HYCS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
@@ -27032,10 +27083,12 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [C] Cefoxitin screen for methicillin resistance in S. pseudintermediusand S. schleiferi is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
|
||||
"EUCAST 2020" "human" "human" "MIC" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
@@ -27051,6 +27104,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "human" "human" "MIC" "B_STPHY_SCHL" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_SCIR" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_SMLN" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_SMLN" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
@@ -27075,7 +27129,6 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "CIP" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "ERY" "ECOFF" 1 1 FALSE FALSE
|
||||
@@ -27085,6 +27138,7 @@ ND = No ECOFF available."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "MFX" "ECOFF" 0.25 0.25 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "RXT" "ECOFF" 1 1 FALSE FALSE
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_WRNR" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 10.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported \"Susceptible, increased exposure\" (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2020" "ECOFF" "ECOFF" "MIC" "B_STPHY_XYLS" 2 "VAN" "ECOFF" 4 4 FALSE FALSE
|
||||
"EUCAST 2020" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -29210,7 +29264,6 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_LISTR_MNCY" 2 "PEN" "L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)" 1 1 FALSE FALSE
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)" "1.25/23.75 mcg" 29 29 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_LISTR_MNCY" 2 "SXT" "L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)" 0.064 0.064 FALSE FALSE "[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_MCRCC_CSLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_MRGNL_MRGN" 2 "IPM" "Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)" "10 mcg" 50 17 FALSE FALSE "[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_MRGNL_MRGN" 2 "IPM" "Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)" 0.125 4 FALSE FALSE "[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem."
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_MRXLL_CTRR" 2 "AMC" "M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)" "2/1 mcg" 19 19 FALSE FALSE
|
||||
@@ -29897,6 +29950,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_STPHY" 3.1 "TZP" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_STPHY" 3.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST lists this agent in this table for other organisms only"
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_AMRC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_ARCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_ARGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_ARLT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -29940,11 +29994,11 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_STPHY_AURS" 2.1 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_STPHY_AURS" 2 "VAN" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" 2 2 FALSE FALSE "[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_BRLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_BRNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CAEL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CANS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CAPR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CASE" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CGLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CHRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CLDN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CNDM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -29980,7 +30034,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CPTS_URLY" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CRCL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CRNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_CSRM" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_DBCK" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_DRMD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_DRRL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_DVRS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_EDPH" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
@@ -29993,10 +30049,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_FELS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_FLRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_GLLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_HLTL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_HMLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_HMNS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_HMNS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_HMNS_NVBS" 1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_HSNC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_KLOS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_LGDN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "MIC" "Screen" "B_STPHY_LGDN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" 4 4 FALSE FALSE "[2] S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance. | [3] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test."
|
||||
@@ -30005,10 +30063,12 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_LLYD" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_LNTS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_MCRT" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_MRYL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_MSSL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_MUSC" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_NPLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_PRGN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_PRQR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_PSCF" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [C] Cefoxitin screen for methicillin resistance in S. pseudintermedius is less predictive of the presence of mecA than in other staphylococci. Use the oxacillin 1 ug disk with zone diameter breakpoints S>=20, R<20 mm to screen for methicillin resistance."
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_STPHY_PSDN" 2.1 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST gives NA (not applicable)"
|
||||
@@ -30022,6 +30082,7 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_SCCN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_SCHL" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_SCIR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_SHIN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_SMLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_STPHY_SPRP" 2 "AMP" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "2 mcg" 18 18 FALSE FALSE "[A] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_STPHY_SPRP" 2.1 "AMP" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] Most staphylococci are penicillinase producers, which make them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. When staphylococci test as susceptible to benzylpenicillin and cefoxitin they can be reported as susceptible to the above agents. However, the efficacy of oral formulations, particularly phenoxymethylpenicillin, is uncertain. Isolates that test as resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to ?-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin), nafcillin and many cephalosporins. With the exception of ceftaroline and ceftobiprole, cefoxitin-resistant isolates are resistant to all beta-lactam agents. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)."
|
||||
@@ -30034,9 +30095,9 @@ Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm.
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_STPN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_TWNN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_URLY" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_VRTR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_VTLN" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_WRNR" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_XERI" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "Screen" "B_STPHY_XYLS" 2 "FOX" "Staphylococcus (file: Clinical Breakpoint Tables v. 9.0)" "30 mcg" 22 22 FALSE FALSE "[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 4/D and 6/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S>=25, R<25 mm."
|
||||
"EUCAST 2019" "human" "human" "DISK" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
"EUCAST 2019" "human" "human" "MIC" "B_STRPT_ABCG" 2.6 "AMC" "Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)" FALSE FALSE "[No breakpoint] EUCAST gives Note (see note) | [1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit."
|
||||
@@ -38637,14 +38698,6 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
|
||||
"CLSI 2026" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "TZD" "Table 2H-2" 0.25 FALSE FALSE
|
||||
"CLSI 2026" "human" "human" "DISK" "B_STRPT_VIRI" 2.5 "VAN" "Table 2H-2" "30 mcg" 17 FALSE FALSE
|
||||
"CLSI 2026" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "VAN" "Table 2H-2" 1 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2026" "human" "human" "MIC" "B_TSKMR" 3 "AMC" "M24 Table 7" 8 32 FALSE FALSE
|
||||
"CLSI 2026" "human" "human" "MIC" "B_TSKMR" 3 "AMK" "M24 Table 7" 8 16 FALSE FALSE
|
||||
"CLSI 2026" "human" "human" "MIC" "B_TSKMR" 3 "CIP" "M24 Table 7" 1 4 FALSE FALSE
|
||||
@@ -39106,6 +39159,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_NKSMY_BRTS" 2 "VOR" "M59 Table 1" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "AMB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 2 2 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"CLSI 2026" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "MIC" "B_ABTRP" 3 "AMP" "M45 Table 1" 0.25 8 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "MIC" "B_ABTRP" 3 "CHL" "M45 Table 1" 4 8 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "MIC" "B_ABTRP" 3 "CIP" "M45 Table 1" 1 4 FALSE FALSE
|
||||
@@ -41264,14 +41325,6 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
|
||||
"CLSI 2025" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "TZD" "Table 2H-2" 0.25 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "DISK" "B_STRPT_VIRI" 2.5 "VAN" "Table 2H-2" "30 mcg" 17 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "VAN" "Table 2H-2" 1 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "MIC" "B_TSKMR" 3 "AMC" "M24 Table 7" 8 32 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "MIC" "B_TSKMR" 3 "AMK" "M24 Table 7" 8 16 FALSE FALSE
|
||||
"CLSI 2025" "human" "human" "MIC" "B_TSKMR" 3 "CIP" "M24 Table 7" 1 4 FALSE FALSE
|
||||
@@ -41730,6 +41783,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_NKSMY_BRTS" 2 "VOR" "M59 Table 1" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "AMB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 2 2 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"CLSI 2025" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "MIC" "B_ABTRP" 3 "AMP" "M45 Table 1" 0.25 8 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "MIC" "B_ABTRP" 3 "CHL" "M45 Table 1" 4 8 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "MIC" "B_ABTRP" 3 "CIP" "M45 Table 1" 1 4 FALSE FALSE
|
||||
@@ -43889,14 +43950,6 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
|
||||
"CLSI 2024" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "TZD" "Table 2H-2" 0.25 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "DISK" "B_STRPT_VIRI" 2.5 "VAN" "Table 2H-2" "30 mcg" 17 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "MIC" "B_STRPT_VIRI" 2.5 "VAN" "Table 2H-2" 1 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_MNTG_INDT" 1 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "B_TRCHP_RBRM" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "MIC" "B_TSKMR" 3 "AMC" "M24 Table 7" 8 32 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "MIC" "B_TSKMR" 3 "AMK" "M24 Table 7" 8 16 FALSE FALSE
|
||||
"CLSI 2024" "human" "human" "MIC" "B_TSKMR" 3 "CIP" "M24 Table 7" 1 4 FALSE FALSE
|
||||
@@ -44355,6 +44408,14 @@ Some countries prefer to categorise wild-type isolates of E. coli and P. mirabil
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_NKSMY_BRTS" 2 "VOR" "M59 Table 1" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "AMB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_SCCHR_CRVS" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 2 2 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.5 0.5 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_INDT" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 1 1 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "AMO" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "ITR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.25 0.25 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "TRB" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.032 0.032 FALSE FALSE
|
||||
"CLSI 2024" "ECOFF" "ECOFF" "MIC" "F_TRCHP_RBRM" 2 "VOR" "Copied from EUCAST 2024 Antifungal ECOFFs" 0.125 0.125 FALSE FALSE
|
||||
"CLSI 2023" "human" "human" "MIC" "B_ABTRP" 3 "AMP" "M45 Table 1" 0.25 8 FALSE FALSE
|
||||
"CLSI 2023" "human" "human" "MIC" "B_ABTRP" 3 "CHL" "M45 Table 1" 4 8 FALSE FALSE
|
||||
"CLSI 2023" "human" "human" "MIC" "B_ABTRP" 3 "CIP" "M45 Table 1" 1 4 FALSE FALSE
|
||||
|
||||
Reference in new issue
Block a user